Dutasteride Hair Loss Fda
What Does the Future Hold Hair Restoration?
Restore lost hair due to hereditary factors, is the dream of many men and women suffering from hair loss. Until not too long ago, the only effective and authentic-looking options to reverse hair loss are not surgical cover-ups. It was only with the arrival of FUT and the discovery of the truth the cause of baldness – the harmful effects of dihydrotestosterone (DHT) in hair follicles – the loss of hair suffererâ € ™ s chances of reversing the natural state had improved considerably.
The three best weapons in the fight against hair loss available today are the two FDA-approved drugs â € "finasteride (Propecia) and minoxidil (Rogaine / Regaine) and hair surgery, transplantation of follicular units and, above all, the technique of follicular unit extraction. However, no definitive cure exists, however, as each of the three hair restoration methods mentioned above has its limitations. Minoxidil and Finasteride work well only in the vertex of the scalp area, and finasteride, can not be used by women. Hair transplants for women is appropriate only for people who have enough hair density in the donor area, and many, who usually suffer from diffuse thinning, it is best for hair transplant surgery.
By Therefore, scientists around the world are constantly seeking new approaches for treating baldness. Currently there are several promising drugs and new developing techniques below, but progress appears to have declined recently due to the global financial crisis, as some R & D projects are becoming increasingly difficult to raise funding to continue their investigations.
Most progress has been achieved (for more information, please go to: http://www.greyhairloss.com/blog/dutasteride-for-hair-loss.html). Dutasteride is a antiandrogen drug, in its chemical structure and mode of action is similar to finasteride. Used to treat benign prostatic hyperplasia (enlarged prostate) and from a dual inhibitor of 5 alpha reductase, which should be a more powerful DHT blocker to finasteride. Therefore, is believed to be more effective in the treatment of hair loss, especially in the frontal scalp area. Dutasteride completed Phase III clinical trials this year and the results the study is expected to be published shortly.
NEOSH101 was originally developed by the U.S. Neosil medical research company and was until tested shortly Phase IIb. In late 2008, was acquired by Neosil Peplin, Inc., a development stage specialty pharmaceutical company, and since then no information on new developments in clinical trials has been released. In previous clinical trials, NEOSH101 has proved more potent and rapid acting hair growth stimulant minoxidil and only need to apply once a day. Despite the significant improvement of current treatment options, hair loss, NEOSH101 not going to be the cure for baldness. Clinical trials appear to be moving slower than most patients would like hair loss, and So do not hold your breath waiting to hit the market in the short term.
Another promising area is the research development of telomerase. Telomerase is an enzyme that is able to put natural limits of telomeres and thus protect them from the lard. The telomerase which maintains genomic integrity. The telomeres Shorts are associated with the cause of premature aging processes. However, uncontrolled activation of telomerase can cause cancer. Cancer research is the main objective of telomerase research, but scientists are also looking for other applications, such as anti-aging and anti-baldness drugs and gray hair. Telomerase research could really change the world of medicine, but its commercial application could be a good 15 years away.
Hair Multiplication, often called hair cloning or hair regeneration, is the next treatment option, hoping to be explored. This technique involves removing hair follicles from the back of the head of the patient, the cultivation and propagation of them and injection of new hair cells become bald scalp. The UK health Intercytex company seems to be the pioneer in the investigation of the multiplication of hair. Intercytex has already completed Phase II trial of ICX-TRC (suspending the patient's own dermal papilla cells). The main benefit of hair multiplication would solving the shortage of donor hair, which is the main limiting factor in hair transplantation. However, Intercytex is currently in financial difficulties and then not find an investor, you will need to continue operating on its own. Aderans, Intercytex's main competitor, has also recently launched a Phase II clinical development of cell-based regeneration of hair for men and women.
Generating new hair follicles in the hair of the wounds free skin is a totally new approach to re-grow lost hair. It was discovered accidentally when skin wounds in mice began to produce new hair. This technology is being developed by U.S. company medical devices, Follica, which has licensed the technology from the University of Pennsylvania. Although this method may sound strange, it is said that only the use of common tools and medicines that have been medically approved and therefore can not take too long to make it available to the public.
This list of projects submitted in the research of hair loss includes the most promising lines development, but not exhaustive. However, none of the new therapies, with the exception of dutasterideâ € ™ s application for the treatment of loss hair in men is expected to reach the market before 2013 and the immediate future of hair restoration is the improvement of surgical techniques, increased yields of the follicular unit extraction method and make it more affordable to a larger portion of the population.
About the Author
For more information on novel as well as existing treatments for hair loss and gray hair and for hair loss product reviews written by real consumers, please visit the author’s website and do not be ashamed to contribute your own review on the hair treatments and therapies you have used, in order to help others assess the potency of existing hair loss treatment options.